ClearPoint Neuro sees 2026 revenue between $48 mln and $52 mln
Company expects 10-15 clinical trials using its technology to be enrolling in next 18 months
Company expects first GLP preclinical services project at CAL to complete in H1 2027
Overview
Device and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectations
Gross margin improved to 62% from 60% a year ago
Company cut 2026 revenue guidance to $48-52 mln, citing shift to clinical support and product development
Result Drivers
Biologics and drug delivery decline - Co said segment revenue fell 15% due to lower product shipments for new biopharma trial initiations, partially offset by growth in preclinical service revenue
Neurosurgery navigation growth - Neurosurgery navigation and therapy revenue rose 62%, driven by IRRAflow product sales and new navigation software, which boosted procedural volumes
Operating expenses rise - Operating expenses rose 51% mainly due to the IRRAS acquisition, higher personnel costs, and increased occupancy and travel costs
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $30.00, about 100.8% above its July 31 closing price of $14.94
CLPT•
